Literature DB >> 10702818

Clotting alterations in primary systemic amyloidosis.

G Gamba1, N Montani, E Anesi, G Palladini, M Capezzera, E Soldavini, G Merlini.   

Abstract

BACKGROUND AND
OBJECTIVE: The bleeding manifestations frequently observed in patients with immunoglobulin light chain amyloidosis (AL) have been attributed to different pathogenetic factors: amyloid deposits in several organs and systems leading to failures of these latter, the affinity of amyloid for some clotting factors, and the presence of plasma components interfering with fibrin formation could all induce alterations of clotting tests. This investigation was aimed at defining the prevalence of clotting abnormalities and their clinical manifestations in patients with AL. DESIGN AND METHODS: Thirty-six consecutive patients with biopsy proven amyloidosis and documented monoclonal gammapathy were enrolled within one year. The following clotting tests were considered in the study: activated partial thromboplastin time (aPTT), prothrombin time (PT), thrombin time (TT), reptilase time (RT), Russell's viper venom time (RVTT), fibrinogen, factor X and alpha-2 antiplasmin.
RESULTS: Hemorrhagic manifestations were mild to moderate in nine patients, but severe and untractable in one. The most frequent clotting anomaly was defective fibrinogen conversion to fibrin, as demonstrated by prolongation of both TT (85% of cases) and RT (90% of cases). Low levels of factor X activity were observed in about 1 out of 4 samples, while fibrinogen and alpha2 antiplasmin levels were distributed over a wide range of values. PT was prolonged in 8 and aPTT in 25 patients. The search for lupus anticoagulant was negative in samples showing a prolongation of aPTT and/or RVVT. INTERPRETATION AND
CONCLUSIONS: The prolongation of TT and RT is not dependent on either the presence of a heparin-like substance in the plasma or on fibrinogen levels; furthermore, the prolongation of RVVT is not related to factor X level. The hypothesized presence in the plasma of an inhibitor of fibrin formation could also affect factor X activation by Russell viper venom. The prolongation of TT and RT represents a peculiar feature of amyloidosis. The variability in the behavior of the other clotting times and hemostatic factors studied is mirrored in the heterogeneity of the clinical features observed in this disease.

Entities:  

Mesh:

Year:  2000        PMID: 10702818

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  7 in total

1.  Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis.

Authors:  Katherine M Bever; Luke I Masha; Fangui Sun; Lauren Stern; Andrea Havasi; John L Berk; Vaishali Sanchorawala; David C Seldin; J Mark Sloan
Journal:  Haematologica       Date:  2015-10-09       Impact factor: 9.941

2.  Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid.

Authors:  Masahisa Arahata; Hiroyuki Takamatsu; Eriko Morishita; Yasuko Kadohira; Shinya Yamada; Akitada Ichinose; Hidesaku Asakura
Journal:  Int J Hematol       Date:  2020-01-03       Impact factor: 2.490

3.  Autopsy findings in a patient with primary systemic AL (kappa light chain) amyloidosis.

Authors:  Felipe Lourenço Ledesma; Jussara Bianchi Castelli
Journal:  Autops Case Rep       Date:  2021-05-06

4.  Acquired factor X deficiency in light chain amyloidosis: a report of 2 Korean cases.

Authors:  Youngeun Ma; Eui-Hoon Kwon; Jung-Eun Lee; Kihyun Kim; Hee-Jin Kim; Sun-Hee Kim
Journal:  Korean J Lab Med       Date:  2011-06-28

5.  AL Amyloidosis Complicated by Persistent Oral Bleeding.

Authors:  Luiz Antonio Liarte Marconcini; Forrest Marc Stewart; Lisa Sonntag; Emily Stevens; Nicholas Burwick
Journal:  Case Rep Hematol       Date:  2015-05-07

6.  Elevation of Plasmin-α2-plasmin Inhibitor Complex Predicts the Diagnosis of Systemic AL Amyloidosis in Patients with Monoclonal Protein.

Authors:  Kazuya Ishiguro; Toshiaki Hayashi; Yoshihiro Yokoyama; Yuka Aoki; Kei Onodera; Hiroshi Ikeda; Tadao Ishida; Hiroshi Nakase
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

7.  A Rare Cause of Coagulopathy in a Patient with Rapidly Progressive Renal Failure.

Authors:  Rudreshwar Prabakaran; Jasmine Sethi; Manish Rathi; Harbir Singh Kohli; Pankaj Malhotra; Krishan Lal Gupta
Journal:  Indian J Nephrol       Date:  2020-02-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.